Core Viewpoint - The approval of the inhalation powder formulation of Nintedanib by the National Medical Products Administration of China marks a significant advancement for the company in the treatment of idiopathic pulmonary fibrosis (IPF) [1] Company Summary - The stock price of the company, CSPC Pharmaceutical Group (01093), increased by over 4% in the morning session, currently trading at HKD 8.81 with a transaction volume of HKD 595 million [1] - The inhalation formulation of Nintedanib is the first inhaled drug approved in China for clinical trials aimed at treating pulmonary fibrosis [1] Product Summary - Nintedanib is a multi-tyrosine kinase inhibitor that can slow the progression of IPF, with the oral formulation currently available as soft capsules [1] - The inhalation formulation offers significant advantages over the oral version, including improved lung exposure, better lung function, reduced systemic exposure, and significantly lower gastrointestinal side effects [1] - Preclinical studies indicate that the inhalation product can achieve equivalent efficacy at 1/200 of the oral dosage, demonstrating good safety and effectiveness [1]

Group 1 - The core viewpoint of the news is that the A-share and Hong Kong markets are experiencing a collective rise, with the Shanghai Composite Index surpassing 4000 points, indicating positive market sentiment [1] - The Hong Kong Stock Connect innovative drug index increased by 3.85%, with notable individual stock performances such as Zhaoyan New Drug rising over 11% and Tigermed and Kelun-Bio rising over 6% [1] - According to a report by Changjiang Securities, Zhaoyan New Drug is expected to see a 60% year-on-year growth in offshore outsourcing orders in 2024, driven by domestic safety evaluation demand recovery and resource scarcity [1] Group 2 - The China National Medical Products Administration reported that 76 innovative drugs have been approved for market in China by 2025, setting a historical record [1] - The total amount of authorized transactions for innovative drugs in China has exceeded $130 billion, with over 150 transactions, also a historical high [1] - Currently, China's pipeline of new drugs accounts for approximately 30% of the global total, ranking second worldwide [1] Group 3 - The Hong Kong Stock Connect innovative drug ETF managed by Harvest (520970) has a management and custody fee of 0.60% per year, making it suitable for both retail investors as a long-term investment tool and for professional investors seeking flexible trading options [2]

Group 1: Market Performance - The Hong Kong stock market experienced a strong start in 2026, with the Hang Seng Index rising by 2.76% to 26,338.47 points, and the Hang Seng Technology Index increasing by 4% to 5,736.44 points [3] - The Hong Kong Innovation Drug ETF (159570) surged over 5.5%, with a trading volume exceeding 1.6 billion yuan, marking a significant increase compared to the previous trading day [1][3] - As of December 29, 2025, the latest scale of the Hong Kong Innovation Drug ETF reached over 21.4 billion yuan, leading its peers in the same category [1] Group 2: Company News - In a significant development, Insilico Medicine announced a multi-year research collaboration with Servier worth up to $888 million, focusing on oncology drug development [3] - The collaboration will leverage Insilico's AI-driven drug discovery platform, Pharma.AI, in conjunction with Servier's global expertise in oncology [3] - Insilico is eligible for an upfront payment of up to $32 million and milestone payments related to research achievements [3] Group 3: Industry Trends - In 2025, the Chinese innovative drug industry set a record for outbound licensing transactions, with a total transaction value of $135.655 billion and 157 deals, marking a historical high [5] - The industry is witnessing a diversification in business development (BD) models, with an increasing number of innovative drug companies opting for co-development partnerships with multinational pharmaceutical firms [7][10] - The "Co-Co" (Co-development & Co-commercialization) model is emerging as a significant trend in 2025, exemplified by the $11.4 billion deal between Innovent Biologics and Takeda [11]

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (520880) has shown significant upward movement, with a peak increase of over 4% and a trading volume exceeding 258 million yuan, surpassing the previous day's total [1]. Group 1: Market Performance - The ETF opened at 0.516, experiencing a rise of 0.018 (3.61%) during trading [1]. - The trading volume reached 2.58 billion yuan, indicating strong market interest [1]. - The ETF has seen a decline of 7.53% over the past 20 days and 17.04% over the past 60 days, reflecting recent market volatility [1]. Group 2: Industry Insights - The National Medical Products Administration reported that 76 innovative drugs were approved for market in China by 2025, significantly exceeding the 48 approved in 2024, marking a historical high [1]. - The total transaction value for innovative drug licensing in 2025 is projected to exceed 130 billion USD, with over 150 licensing transactions, also a record high [1]. Group 3: Investment Strategy - Analysts from Zhongyou Securities suggest that the maturity of clinical data will be a key driver for the innovative drug market in 2026, with business development (BD) becoming a necessary outcome of enhanced competitiveness for domestic new drugs [2]. - The current period is viewed as an optimal configuration window for the Hong Kong Stock Connect innovative drug sector, following a three-month adjustment that began in September 2025 [2]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has unique advantages, including a focus on pure innovative drug companies and a high concentration of leading firms [2][4]. Group 4: ETF Composition - The top ten holdings in the ETF account for over 72% of its weight, showcasing the dominance of leading innovative drug companies [4]. - Notable companies within the ETF include BeiGene (11.51% weight), Innovent Biologics (10.19%), and China National Pharmaceutical Group (9.47%) [4]. Group 5: Alternative Investment Options - For investors seeking to mitigate volatility while still focusing on innovative drugs, the market offers the only ETF (562050) that combines innovative drugs with traditional Chinese medicine, providing a balanced approach [4].

Group 1 - The core viewpoint of the news is that the Hong Kong Stock Connect innovative drug sector is experiencing a significant rally, with leading stocks showing strong gains, indicating a positive market sentiment towards innovative pharmaceuticals [1][3]. - The China National Medical Products Administration reported that 76 innovative drugs were approved for market in 2025, surpassing the total of 48 in 2024, marking a historical high [3]. - The total value of authorized transactions for innovative drugs in China exceeded $130 billion in 2025, with over 150 transactions, also setting a new record [3]. Group 2 - The Hong Kong Stock Connect innovative drug ETF (520880) saw a notable increase, with a peak rise of over 4% and a trading volume of 258 million yuan, surpassing the previous trading day's total [1]. - The ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three unique advantages: it is purely focused on innovative drug companies, has a high concentration of leading firms, and offers better risk control by reducing the weight of less liquid stocks [3][4]. - The top ten holdings in the ETF account for over 72% of the index's weight, highlighting the dominance of leading innovative drug companies [4].

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector experienced a significant rally, with leading stocks such as BeiGene and Innovent Biologics rising nearly 5% and over 5% respectively, indicating strong market interest in innovative pharmaceuticals [1][7]. Group 1: Market Performance - The Hong Kong Stock Connect innovative drug ETF (520880) opened with a continuous rise, peaking at over 4% increase, with a trading volume of 258 million yuan, surpassing the previous trading day's total [1][8]. - Major stocks in the innovative drug sector, including BeiGene, Innovent Biologics, and CSPC Pharmaceutical Group, saw increases of nearly 5% and over 3% respectively, reflecting a positive market sentiment [1][7]. Group 2: Regulatory and Market Developments - The National Medical Products Administration reported that 76 innovative drugs were approved for market in China in 2025, significantly exceeding the 48 approved in 2024, marking a historical high [1][10]. - The total value of authorized transactions for innovative drugs in China exceeded $130 billion in 2025, with over 150 transactions, also setting a new record [1][10]. Group 3: Investment Insights - Analysts from Zhongyou Securities suggest that the maturity of clinical data will be a key driver for the innovative drug market in 2026, with business development (BD) expected to enhance the competitiveness of domestic new drugs [3][10]. - The current period is viewed as an optimal configuration window for the Hong Kong Stock Connect innovative drug sector, following a three-month adjustment that began in September 2025 [3][10]. - The Hong Kong Stock Connect innovative drug ETF (520880) and its associated funds track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which boasts significant advantages such as comprehensive coverage of innovative drug companies and a high concentration of leading firms [3][10]. Group 4: ETF Composition - The top ten holdings in the Hong Kong Stock Connect innovative drug ETF account for over 72% of the total weight, highlighting the dominance of leading companies in the sector [4][11]. - Key constituents include BeiGene (11.51% weight), Innovent Biologics (10.19%), and China Biologic Products (9.47%), among others, indicating a strong representation of major players in the innovative drug market [4][11]. Group 5: Alternative Investment Options - For investors seeking exposure to innovative drugs while mitigating volatility, the unique A-share drug ETF (562050) is recommended, which focuses on the top 50 A-share pharmaceutical companies, balancing innovative drugs with traditional Chinese medicine [4][12].

Group 1 - The Hong Kong stock market's innovative drug concept stocks are experiencing a continuous rebound, with notable increases in share prices [1] - Specifically, Gilead Sciences-B has risen nearly 10%, while Zhaoyan New Drug has increased by over 8% [1] - Other companies such as Tigermed, Innovent Biologics, and CSPC Pharmaceutical Group have also seen their stock prices rise significantly [1]

Market Performance - The Hang Seng Index opened up 0.09% at 26,361.44 points, while the Hang Seng Tech Index rose 0.33% to 5,755.28 points. The National Enterprises Index fell 0.03% to 9,166.25 points, and the Red Chip Index decreased by 0.22% to 4,074.78 points [1] - Major tech stocks showed mixed performance: Alibaba-W increased by 1.41%, Tencent Holdings rose by 0.16%, JD.com-SW fell by 0.26%, Xiaomi Group-W gained 0.79%, NetEase-S dropped 0.26%, Meituan-W decreased by 0.38%, Kuaishou-W surged by 5.89%, and Bilibili-W rose by 0.85% [1] - The three major indices in Hong Kong experienced a "New Year rally" on the last trading day, with the Hang Seng Index up 2.76% to 26,338.47 points, the Tech Index up 4% to 5,736.44 points, and the National Enterprises Index up 2.86% to 9,168.99 points [1] Investment Insights - CICC analyzed that the recent surge is likely not due to significant capital inflow or major policy changes, but rather driven by industry factors such as the listing of semiconductor leaders and the end of overseas holidays prompting investors to reposition for 2026 [2] - Huatai Securities recommends continuing to allocate to tech chains with performance expectations, while also considering a balanced allocation to cash flow assets due to changing driving factors and funding attributes [2] - Key sectors to watch in Q1 include strong cyclical industries with external demand catalysts, such as copper, aluminum, chemicals, and engineering machinery, alongside technology as a main focus [2] Company News - BYD is projected to achieve total sales of 4.602 million new energy vehicles in 2025, with pure electric vehicle sales expected to reach approximately 2.257 million units, marking a year-on-year increase of 27.86% [6] - Semiconductor industry developments are highlighted by the increase in the shareholding of the National Integrated Circuit Industry Investment Fund in SMIC from 4.79% to 9.25% [10] - The China Securities Regulatory Commission has revised regulations to lower public fund sales costs, which is expected to save investors approximately 51 billion yuan annually, reducing the comprehensive fee rate by about 20% [9]

在上一期《巨头的in vivo CAR-T方向（上）：LNP-RNA价格更高》中，小编盘点了一下四笔体内CAR-T公司并购案，得出结论：在市场交易中，买家对 LNP-RNA的体内CAR-T策略的心理价位更高。 这期，我们继续来盘，另外几家大型制药公司的体内CAR-T选择方向。 安斯泰来 2024年2月，安斯泰来子公司Xyphos Biosciences与Kelonia Therapeutics达成合作，共同开发基于工程化慢病毒病毒载体的体内CAR-T细胞治疗，潜在交易 总额超8.75亿美元。 双方将结合Kelonia专有的iGPS®（体内基因定位系统）技术与Xyphos的免疫细胞convertibleCAR（convertible Chimeric Antigen Receptor，可转化嵌合抗原 受体）平台ACCEL™，共同开发下一代肿瘤免疫治疗药物体内CAR-T细胞。 iGPS®（体内基因定位系统）是一种基于慢病毒载体的体内基因递送技术平台，其通过对慢病毒进行修饰以提高体内基因转导效率，并对慢病毒进行工程 化使其表达趋向性分子以实现组织特异性。 根据协议，该合作的目标项目最多可达两个。Kelonia将首先 ...

Group 1 - Baidu Group-SW (09888) proposes to spin off Kunlun Chip for independent listing on the Hong Kong Stock Exchange main board [1] - Dali Group Holdings (01921) subsidiary Dali International Industrial Company has obtained a temporary industrial license issued by MIMR [1] - Guofu Hydrogen Energy (02582) has completed the delivery of a total of 424 sets of vehicle-mounted high-pressure hydrogen supply systems to its customers [1] Group 2 - CSPC Pharmaceutical Group (01093) has received clinical trial approval in China for its inhalation powder of Nintedanib [1] - Fantasia Holdings (01777) has entered into a restructuring agreement with Splendid Fortune to sell 409 million shares of Color Life for USD 4.5284 million [1] - China Hongqiao (01378) has made Hongtuo Industrial a wholly-owned subsidiary of Hongchuang Holdings [1] Group 3 - Brainstorm Cell Therapeutics-B (06681) subsidiary has officially signed a cooperation agreement with Beijing Jianguo Medical for a cognitive digital therapy project [1] - Longpan Technology (02465) plans to invest in a lithium iron phosphate production base with an annual capacity of 240,000 tons, with a total investment not exceeding 2 billion yuan [1] - Zhongzheng International (00943) intends to acquire a digital solution company in the beauty industry for HKD 62.5 million, with resumption of trading on January 5 [1] - Kelun-Biotech (06990) has received approval from the National Medical Products Administration for the clinical trial application of its ITGB6 ADC SKB105 new drug [1]